Clinical Trial

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIb/III clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity profile of Efsubaglutide Alfa injection in overweight and obese subjects. The primary endpoint of the Phase IIb is the percentage change in body weight from baseline after 18 weeks of treatment. The primary endpoint of the Phase III is the percentage change in body weight from baseline after 30 weeks of treatment, the secondary endpoint is the percentage change in body weight from baseline after a cumulative 48 weeks of treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-08; most recent amendment 2026-01-29.
Status change: Recruiting → Active, Not Recruiting 2026-01-29
Trial Details
NCT Number NCT06921486
Lead Sponsor Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Conditions Obesity and Overweight
Enrollment 1,003 participants
Start Date 2025-03-31
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-30